Despite the improvement in response rates of women with HER2-positive breast cancer to trastuzumab based treatments, a significant population of women have innate resistance to the trastuzumab based treatments such as the standard of care, TCH based therapy [2–5]. This evidence concerns the gene ERBB2 and breast cancer.